[Skip to Content]
[Skip to Content Landing]
Other Articles
July 24, 1937


JAMA. 1937;109(4):294. doi:10.1001/jama.1937.02780300050025

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  With regard to the article in The Journal on "Dinitrophenol and Desiccated Thyroid in the Treatment of Obesity," by Dr. Samuel Simkins (June 19, p. 2110, June 26, p. 2193), I wish to express my appreciation of the high quality of the arbeit. In the concluding paragraph in the summary the recommendation is made that "the indiscriminate clinical use of dinitrophenol should be discontinued until the vexing problem of cataracts complicating dinitrophenol therapy is solved." I would suggest that at the present time the profession follow it, omitting the adjective "indiscriminate." The great trouble is that we are not able to discriminate. Is it not enough to know that the drug is extremely toxic and that we should not employ it in the treatment of obesity?Recently an article appeared in a Mayo Clinic publication stating that the authors used cinchophen in the treatment of gout. Of

First Page Preview View Large
First page PDF preview
First page PDF preview